Drugs / GCFLU Quadrivalent
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT03718468 | Oct 2018 → Jul 2019 | influenza | Medigen Vaccine Biologics Corp. | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1 | NCT03357263 Comparator | Nov → Dec 2017 | influenza | Green Cross Corporation | Completed | No outcome recorded |
| Phase 2 | NCT03657719 Comparator | Oct → Dec 2018 | influenza | Green Cross Corporation | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GCFLU Quadrivalent | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03357263 ↗ |
| Known as | GC FLU | “This study aims to demonstrate the immunogenic efficacy of GC FLU Quadrivalent Pre-filled Syringe inj. (GC FLU), a quadrivalent influenza virus vaccine, is non-inferior to the...” NCT03718468 ↗ |
| Modality | Vaccine | “Quadrivalent influenza vaccine” NCT03357263 ↗ |
| Route | Intramuscular | “Pre-filled syringe inj., 0.5ml, Once, IM” NCT03357263 ↗ |